Dectin-1 induces TRPV1 sensitization and contributes to visceral hypersensitivity of irritable bowel syndrome in male mice.

Researchers studied why people with irritable bowel syndrome (IBS) experience abdominal pain and heightened sensitivity in their digestive tract. The study focused on male mice and examined how fungal imbalances in the gut might contribute to visceral hypersensitivity—the medical term for when the intestines become overly sensitive to normal sensations, turning them into painful experiences.

Scientists discovered that a protein called Dectin-1, which normally helps the body recognize fungi, plays an important role in triggering this pain sensitivity. When they used antifungal medications (fluconazole and nystatin), blocked Dectin-1 activity, or used mice genetically modified to lack this protein, the animals showed reduced visceral hypersensitivity. The research revealed that Dectin-1 works by sensitizing pain receptors called TRPV1 channels in nerve cells, making them more responsive to stimuli.

This finding is significant because it suggests that fungal overgrowth in the gut may be an overlooked contributor to chronic abdominal pain in IBS patients. The study proposes that controlling intestinal fungi could help treat stubborn abdominal pain in people with IBS or inflammatory bowel disease in remission.

For patients considering acupuncture for IBS-related abdominal pain, this research supports a comprehensive approach to treatment. While the study focused on the fungal-nerve connection, acupuncture has been shown in other research to modulate pain pathways and reduce visceral hypersensitivity through different mechanisms. Combining acupuncture with appropriate medical management—including potential antifungal therapy when fungal dysbiosis is suspected—may offer enhanced relief for chronic digestive pain. Always consult with a qualified, licensed acupuncturist who has experience treating gastrointestinal conditions.

This preclinical study investigated Dectin-1's role in visceral hypersensitivity using male mice with TNBS-induced colitis (0.1 mL TNBS, 130 μg/mL in 30% ethanol, intracolonic administration). Researchers employed antifungal pretreatment (fluconazole, nystatin), Dectin-1 antagonist (laminarin), and Clec7a-/- knockout mice. Visceral sensitivity was assessed via colorectal distension-electromyogram recording.

Key findings demonstrated that blocking Dectin-1 activity significantly attenuated TNBS-induced visceral hypersensitivity. Dectin-1 expression was upregulated in dorsal root ganglia and colonic tissue. Immunostaining revealed Dectin-1/TRPV1 colocalization in DRG neurons. Calcium imaging confirmed that Dectin-1 agonist (curdlan) enhanced TRPV1-mediated calcium influx, demonstrating functional TRPV1 sensitization.

Clinical implications: This research establishes a fungal dysbiosis-Dectin-1-TRPV1 pathway contributing to visceral pain. For practitioners treating refractory IBS or IBD-related abdominal pain, this suggests potential benefit from addressing fungal overgrowth alongside conventional treatments. Acupuncture's documented effects on visceral hypersensitivity and TRPV1 modulation may complement antifungal strategies in managing chronic abdominal pain resistant to standard therapies.